Tracking Blood Sugar Changes During Treatment for Ketosis-Prone Diabetes
Studies day-to-day blood sugar changes in adults with ketosis-prone diabetes using glucose monitors and insulin.
Plain-language title generated from the registry record
Registry title: Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
Key facts
- Where
- Atlanta, United StatesSee the 2 sites
- Phase
- Phase 4
Where in United States
- Emory University Hospital MidtownAtlanta, United StatesTaking people
- Grady Health SystemAtlanta, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Emory University
- Trial code
- NCT06699810
- Record updated
- 15 June 2026
- Original description
The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.Read full original descriptionShow less
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.
Inclusion: Provide informed consent; Have a BMI ≥ 28 kg/m2; Be of African American ancestry; Meet diagnostic criteria for DKA. Diagnostic criteria for DKA will include a plasma glucose > 250 mg/dl, a venous pH < 7.30, a serum bicarbonate < 18 mmol/l, and serum ketones (beta-hydroxy butyrate) > 1.5 mmol/L.
Exclusion: Diagnosis of diabetes > 90 days before the presentation of DKA; Have recognized uncontrolled endocrine disorders such as hypercortisolism, acromegaly, or hyperthyroidism; Significant medical or surgical illness including but not limited to myocardial ischemia, congestive heart failure, chronic peripheral venous insufficiency, chronic renal insufficiency, liver insufficiency (serum transaminases 3 times the upper limit of normal) and acute or chronic infectious processes; Anemia (hemoglobin < 12.5 g/dL for men, <11.5 gm/dL for women), bleeding disorders, or abnormalities in coagulation studies; Pregnant; Unable to give consent.